ArticleCancers2021
Survival Outcomes with Photodynamic Therapy, Chemotherapy and Radiation in Patients with Stage III or Stage IV Non-Small Cell Lung Cancer.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Bronchoscopic photodynamic therapy for endobronchial metastatic papillary thyroid carcinoma causing lobar airway obstruction: a case report.Annals of translational medicine · 2026Article
- International Consensus on Severe Lung Cancer-The Second Edition.Translational lung cancer research · 2026Review
- Photodynamic Therapy Combined with Anticancer Drug Therapy in the Treatment of Malignant Neoplasms.Cells · 2026Review
- Photodynamic therapy-induced inflammation and adverse effects: An updated review.Biomedical journal · 2026Review
- Hyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases.Oncology · 2026Article
- Combined Photodynamic Therapy and Chemotherapy Using Local Intra-Arterial Intratumoral Administration of Chlorin e6 and Cisplatin: First Clinical Observations.International journal of molecular sciences · 2025Article
- Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy.Small science · 2025Article
- Next-Generation Photosensitizers: Cyanine-Carborane Salts for Superior Photodynamic Therapy of Metastatic Cancer.Angewandte Chemie (International ed. in English) · 2025Article
- Advancements in Nanocarrier Delivery Systems for Photodynamic Therapy in Lung Cancer.International journal of nanomedicine · 2025Review
- Comparison of the Differences between Two-Photon Excitation, Upconversion, and Conventional Photodynamic Therapy on Cancers in In Vitro and In Vivo Studies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- First-In-Human Computer-Optimized Endobronchial Ultrasound-Guided Interstitial Photodynamic Therapy for Patients With Extrabronchial or Endobronchial Obstructing Malignancies.JTO clinical and research reports · 2022Article
- Article
- Biomimetic nanoparticles for tumor immunotherapy.Frontiers in bioengineering and biotechnology · 2022Review
- Bibliometric Analysis of Global Research on Cancer Photodynamic Therapy: Focus on Nano-Related Research.Frontiers in pharmacology · 2022Article
- [Observation of Short-term and Long-term Efficacy of Bronchoscopic Interventional Therapy in the Treatment of Typical Carcinoid].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Data regarding the association between photodynamic therapy (PDT) and mortality in lung cancer patients are limited. We analyzed the association between PDT and mortality in patients with stage III or IV non-small cell lung cancer (NSCLC) using data from the National Cancer Database (NCDB) between 2004 and 2016. From the NCDB, we identified patients receiving laser ablation/cryosurgery or local tumor destruction/excision (which includes PDT). From Medicare and Medicaid claims between 2000 and 2013, we identified NSCLC patients receiving PDT and those receiving bronchoscopy, then used these to confirm the PDT treatment. From NCDB, we extracted NSCLC patients who received radiation with chemotherapy, radiation alone or chemotherapy alone. We used survival analysis to determine the association between PDT and mortality. Between 2004 and 2016, 457,556 NSCLC patients with stage III or stage IV were identified, of which 147 received PDT with radiation and chemotherapy, 227,629 received radiation with chemotherapy, 106,667 had radiation therapy alone and 122,193 received chemotherapy alone. Compared to the radiation alone group, the PDT group and radiation with chemotherapy group had lower hazard of mortality (50% and 53% lower, respectively). Among the NSCLC patients with stage III or stage IV disease, the addition of PDT to radiation therapy offers survival benefit over radiation therapy alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.